OBJECTIVE: The purpose of our study was to evaluate the feasibility and treatment outcomes of fractionated stereotactic radiotherapy (SRT) for primary hepatocellular carcinoma (HCC). METHODS: We enrolled 20 patients who had been histologically diagnosed as HCC patients and treated by fractionated SRT. Tumor size was 2-6.5 cm (average: 3.8 cm). We prescribed 50 Gy in 5 or 10 fractions at the 85-90% isodose line of the planning target volume for 2 weeks. The follow-up period was 3-55 months (median: 23 months). RESULTS: The overall response rate was 80%, with 4 patients showing complete response (20%), 14 patients showing partial response (60%) and 4 patients showing stable disease (20%). The 1-year and 2-year survival rates were 70.0 and 43.1%, respectively (median: 20 months). The 1-year and 2-year disease-free survival rates were 65.0 and 32.5%, respectively (median: 19 months). The fractionated SRT was well tolerated, because grade 3 or grade 4 toxicity was not observed. CONCLUSION: These results suggest that fractionated SRT is a relatively safe and effective method for treating small primary HCC. Thus, fractionated SRT may be suggested as a local treatment of choice for small HCC when the patients are inoperable or when the patients refuse operation.
OBJECTIVE: The purpose of our study was to evaluate the feasibility and treatment outcomes of fractionated stereotactic radiotherapy (SRT) for primary hepatocellular carcinoma (HCC). METHODS: We enrolled 20 patients who had been histologically diagnosed as HCC patients and treated by fractionated SRT. Tumor size was 2-6.5 cm (average: 3.8 cm). We prescribed 50 Gy in 5 or 10 fractions at the 85-90% isodose line of the planning target volume for 2 weeks. The follow-up period was 3-55 months (median: 23 months). RESULTS: The overall response rate was 80%, with 4 patients showing complete response (20%), 14 patients showing partial response (60%) and 4 patients showing stable disease (20%). The 1-year and 2-year survival rates were 70.0 and 43.1%, respectively (median: 20 months). The 1-year and 2-year disease-free survival rates were 65.0 and 32.5%, respectively (median: 19 months). The fractionated SRT was well tolerated, because grade 3 or grade 4 toxicity was not observed. CONCLUSION: These results suggest that fractionated SRT is a relatively safe and effective method for treating small primary HCC. Thus, fractionated SRT may be suggested as a local treatment of choice for small HCC when the patients are inoperable or when the patients refuse operation.
Authors: Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2009-12-08 Impact factor: 66.675
Authors: Rojymon Jacob; Falynn Turley; David T Redden; Souheil Saddekni; Ahmed K A Aal; Kimberly Keene; Eddy Yang; Jessica Zarzour; David Bolus; J Kevin Smith; Stephen Gray; Jared White; Devin E Eckhoff; Derek A DuBay Journal: HPB (Oxford) Date: 2014-09-04 Impact factor: 3.647
Authors: Higinia R Cárdenes; Tracy R Price; Susan M Perkins; Mary Maluccio; P Kwo; T E Breen; Mark A Henderson; Tracey E Schefter; Kathy Tudor; Jill Deluca; Peter A S Johnstone Journal: Clin Transl Oncol Date: 2010-03 Impact factor: 3.405
Authors: Byung Ock Choi; Ihl Bohng Choi; Hong Seok Jang; Young Nam Kang; Ji Sun Jang; Si Hyun Bae; Seung Kew Yoon; Gyu Young Chai; Ki Mun Kang Journal: BMC Cancer Date: 2008-11-27 Impact factor: 4.430